Evidence map›Paper›PMID 25939520›Full record

ReviewClinical rheumatology2015

Biomarkers for diagnosis, monitoring of progression, and treatment responses in ankylosing spondylitis and axial spondyloarthritis.

John D Reveille

2 registry-linked trialsAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinical rheumatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 60 papers.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed
9.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05327140 completednot on this mapstarted 2021, after this paper: background citation

Reliability of Inflammatory Back Pain Criteria and Activity Scores in Patients With Axial Spondyloarthritis

TypeobservationalSponsorZagazig UniversityRan2021 to 2022Enrolled206ConditionsAxial Spondyloarthritis, Inflammatory Back Pain
NCT06642207 recruitingnot on this mapstarted 2024, after this paper: background citation

Effect of IL17 Inhibitor in Comparison With Anti-TNF- α on Platelet Count and Its Association With Disease Activity in Patients With Ankylosing Spondylitis

TypeobservationalSponsorSohag UniversityRan2024 to 2025Enrolled50ConditionsAnkylosing SpondylitisArmsCBC
3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 109 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
  4. [Role of HLA genetic variants in autoimmune diseases].Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2026
    Review
  5. Observational
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

John D ReveilleDivision of Rheumatology and Clinical Immunogenetics, The University of Texas Health Science Center at Houston, 6431 Fannin, MSB 5.270, Houston, TX, 77030, USA, John.D.Reveille@uth.tmc.edu.
The University of Texas Health Science Center at Houston · US

Funding

The Genetic Basis of AS SusceptibilityP01AR052915 · NIAMS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI BROWN, MATTHEW A · 2006 to 2016
$10.9M
NIAMS NIH HHS P01 AR052915
6 · The paper itself

Abstract

With the growing awareness of the impact of chronic back pain and axial spondyloarthritis and recent breakthroughs in genetics and the development of novel treatments which may impact best on early disease, the need for markers that can facilitate early diagnosis and profiling those individuals at the highest risk for a bad outcome has never been greater. The genetic basis of ankylosing spondylitis has been considerably advanced, and HLA-B27 testing has a role in the diagnosis. Knowledge is still incomplete of the rest of the genetic contribution to disease susceptibility, and it is likely premature to use extensive genetic testing (other than HLA-B27) for diagnosis. Serum and plasma biomarkers have been examined extensively in assessing disease activity, treatment response, and as predictors or radiographic severity. For assessing disease activity, other than C-reactive protein and erythrocyte sedimentation rate, the most work has been in examining cytokines (particularly interleukin 17 and 23), matrix metalloproteinase (MMP) markers (particularly MMP3). For assessing those at the highest risk for radiographic progression, biomarkers of bony metabolism, cartilage and connective tissue degradation products, and adipokines have been most extensively assessed. The problem is that no individual biomarkers has been reproducibly shown to assess disease activity or predict outcome, and this area still remains an unmet need, of relevance to industry stakeholders, to regulatory bodies, to the healthcare system, to academic investigators, and finally to patients and providers.

Indexed as

AdipokinesAggrecansBiomarkersBone and BonesCartilageCartilage Oligomeric Matrix ProteinChitinase-3-Like Protein 1Connective TissueCytokinesDisease ProgressionGenetic MarkersHLA-B27 AntigenHumansLectinsLeukocyte L1 Antigen ComplexMatrix MetalloproteinasesAdipokinesAggrecansBiomarkersCartilage Oligomeric Matrix ProteinCHI3L1 protein, humanChitinase-3-Like Protein 1CytokinesGenetic MarkersHLA-B27 AntigenLectinsLeukocyte L1 Antigen ComplexMatrix MetalloproteinasesOsteoprotegerin

Identifiers

PMID25939520
PMCPMC4488904
OpenAlexW2000080391

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.